One-Year Results of Fixed Aflibercept Treatment Regime in Type 3 Neovascularization
Jazyk angličtina Země Švýcarsko Médium print-electronic
Typ dokumentu časopisecké články
PubMed
31121590
DOI
10.1159/000499719
PII: 000499719
Knihovny.cz E-zdroje
- Klíčová slova
- Aflibercept, Age-related macular degeneration, Anti-vascular endothelial growth factor, Optical coherence tomography, Retinal angiomatous proliferation, Type 3 neovascularization,
- MeSH
- injekce intravitreální MeSH
- lidé středního věku MeSH
- lidé MeSH
- macula lutea patologie MeSH
- následné studie MeSH
- optická koherentní tomografie MeSH
- receptory vaskulárního endoteliálního růstového faktoru aplikace a dávkování antagonisté a inhibitory MeSH
- rekombinantní fúzní proteiny aplikace a dávkování MeSH
- retinální pigmentový epitel patologie MeSH
- retrospektivní studie MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- vlhká makulární degenerace diagnóza farmakoterapie MeSH
- vztah mezi dávkou a účinkem léčiva MeSH
- zraková ostrost * MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- aflibercept MeSH Prohlížeč
- receptory vaskulárního endoteliálního růstového faktoru MeSH
- rekombinantní fúzní proteiny MeSH
PURPOSE: To evaluate the effect of intravitreal aflibercept injections in treatment-naive type 3 neovascularization using a fixed treatment regime during the first year of therapy. METHODS: Fourteen eyes of 14 patients diagnosed with type 3 neovascularization were studied. All patients were treated with intravitreal aflibercept injections using a fixed treatment regime of 3 consecutive monthly dosages followed by 2-month interval injections. Results were assessed after a 12-month follow-up period. Changes of best corrected visual acuity (BCVA), central retinal thickness (CRT), central macular volume (CMV), and retinal pigment epithelium (RPE) atrophy at fundus autofluorescence and infrared reflectance images were recorded and analyzed. RESULTS: BCVA improved from 60.3 ± 11.7 ETDRS letters at the baseline to 70.9 ± 10.3 ETDRS letters at 12-months follow-up (p = 0.036). Also, CRT and CMV statistically improved after the treatment (from 425 ± 117 to 308 ± 117 µm [p = 0.031] and from 9.52 ± 1.90 to 8.29 ± 0.95 mm3 [p = 0.073], respectively). In 4 patients, development and progression of RPE atrophy were observed, and it was associated with the presence of serous pigment epithelium detachment at the baseline. Furthermore, the development of a fibrotic lesion eccentric to the fovea was observed in 5 patients, without significant impairment of BCVA (p = 0.290). CONCLUSION: Intravitreal aflibercept administered in a fixed treatment regime during the first year of therapy may be effective for the improvement and stabilization of BCVA in eyes with type 3 neovascularization. However, RPE atrophy and subretinal/intraretinal fibrosis can develop during the treatment.
Axon Clinical Ltd Clinical Research Centre Prague Czechia
Department of Ophthalmology Military University Hospital Prague Prague Czechia
Department of Ophthalmology University Hospital Brno Brno Czechia
Department of Ophthalmology University Vita Salute IRCCS Ospedale San Raffaele Milan Italy
Department of Statistics and Probability University of Economics Prague Prague Czechia
Citace poskytuje Crossref.org